During the forecast period of 2025 to 2032 the market is likely to grow at a CAGR of 9.50%, primarily driven by rising consumer awareness about healthy lifestyles

"Key Optic Neuritis Therapies Include Efgartigimod Alfa, OCS-05 IV Administration, Ravulizumab, B001, Inebilizumab, Divozilimab, MIL62, Satralizumab, Batoclimab, and More"

The global Cosmetics market size was valued at USD 301.2 billion in 2025 and is expected to reach USD 472.5 billion by 2033, at a CAGR of 5.80% during the forecast period.